These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 17371973)

  • 21. CD40-activated B cells contribute to mesothelioma tumor regression.
    Jackaman C; Cornwall S; Graham PT; Nelson DJ
    Immunol Cell Biol; 2011 Feb; 89(2):255-67. PubMed ID: 20628372
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MyD88/CD40 Genetic Adjuvant Function in Cutaneous Atypical Antigen-Presenting Cells Contributes to DNA Vaccine Immunogenicity.
    Collinson-Pautz MR; Slawin KM; Levitt JM; Spencer DM
    PLoS One; 2016; 11(10):e0164547. PubMed ID: 27741278
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human CD14 is an efficient target for recombinant immunoglobulin vaccine constructs that deliver T cell epitopes.
    Tunheim G; Schjetne KW; Fredriksen AB; Sandlie I; Bogen B
    J Leukoc Biol; 2005 Mar; 77(3):303-10. PubMed ID: 15576418
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective antigen presenting activity of cortical thymic epithelial cells against CD4+ T cells associated with both lack of costimulatory molecules and inefficient presentation of MHC-peptide ligands.
    Kaneda R; Iwabuchi K; Kasai M; Murakami M; Uede T; Onoé K
    Cell Immunol; 1997 Nov; 181(2):163-71. PubMed ID: 9398403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire.
    Bioley G; Dousset C; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Ayyoub M; Valmori D
    Clin Cancer Res; 2009 Jul; 15(13):4467-74. PubMed ID: 19531622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication.
    van Mierlo GJ; Boonman ZF; Dumortier HM; den Boer AT; Fransen MF; Nouta J; van der Voort EI; Offringa R; Toes RE; Melief CJ
    J Immunol; 2004 Dec; 173(11):6753-9. PubMed ID: 15557168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen.
    Rice J; Buchan S; Stevenson FK
    J Immunol; 2002 Oct; 169(7):3908-13. PubMed ID: 12244189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a Novel CD4
    Fernandez-Ruiz D; Lau LS; Ghazanfari N; Jones CM; Ng WY; Davey GM; Berthold D; Holz L; Kato Y; Enders MH; Bayarsaikhan G; Hendriks SH; Lansink LIM; Engel JA; Soon MSF; James KR; Cozijnsen A; Mollard V; Uboldi AD; Tonkin CJ; de Koning-Ward TF; Gilson PR; Kaisho T; Haque A; Crabb BS; Carbone FR; McFadden GI; Heath WR
    J Immunol; 2017 Dec; 199(12):4165-4179. PubMed ID: 29084838
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD40-activated B cells induce anti-tumor immunity in vivo.
    Wennhold K; Weber TM; Klein-Gonzalez N; Thelen M; Garcia-Marquez M; Chakupurakal G; Fiedler A; Schlösser HA; Fischer R; Theurich S; Shimabukuro-Vornhagen A; von Bergwelt-Baildon M
    Oncotarget; 2017 Apr; 8(17):27740-27753. PubMed ID: 26934557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo.
    Garcia Casado J; Janda J; Wei J; Chapatte L; Colombetti S; Alves P; Ritter G; Ayyoub M; Valmori D; Chen W; Lévy F
    Eur J Immunol; 2008 Jul; 38(7):1867-76. PubMed ID: 18546142
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD40-targeted recombinant adenovirus significantly enhances the efficacy of antitumor vaccines based on dendritic cells and B cells.
    Kim YS; Kim YJ; Lee JM; Han SH; Ko HJ; Park HJ; Pereboev A; Nguyen HH; Kang CY
    Hum Gene Ther; 2010 Dec; 21(12):1697-706. PubMed ID: 20604681
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies.
    Li F; Ravetch JV
    Science; 2011 Aug; 333(6045):1030-4. PubMed ID: 21852502
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spontaneous Activation of Antigen-presenting Cells by Genes Encoding Truncated Homo-Oligomerizing Derivatives of CD40.
    Levin N; Pato A; Cafri G; Eisenberg G; Peretz T; Margalit A; Lotem M; Gross G
    J Immunother; 2017; 40(2):39-50. PubMed ID: 28005579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
    Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
    Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting dendritic cells in humanized mice receiving adoptive T cells via monoclonal antibodies fused to Flu epitopes.
    Graham JP; Authie P; Yu CI; Zurawski SM; Li XH; Marches F; Flamar AL; Acharya A; Banchereau J; Palucka AK
    Vaccine; 2016 Sep; 34(41):4857-4865. PubMed ID: 27595442
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A dual-function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice.
    Xiang R; Primus FJ; Ruehlmann JM; Niethammer AG; Silletti S; Lode HN; Dolman CS; Gillies SD; Reisfeld RA
    J Immunol; 2001 Oct; 167(8):4560-5. PubMed ID: 11591784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dendritic cell maturation enhances CD8+ T-cell responses to exogenous antigen via a proteasome-independent mechanism of major histocompatibility complex class I loading.
    Robson NC; Beacock-Sharp H; Donachie AM; Mowat AM
    Immunology; 2003 Jul; 109(3):374-83. PubMed ID: 12807483
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells.
    Tanaka Y; Koido S; Ohana M; Liu C; Gong J
    J Immunol; 2005 Feb; 174(3):1274-80. PubMed ID: 15661883
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma.
    Mazzocco M; Martini M; Rosato A; Stefani E; Matucci A; Dalla Santa S; De Sanctis F; Ugel S; Sandri S; Ferrarini G; Cestari T; Ferrari S; Zanovello P; Bronte V; Sartoris S
    Immunology; 2015 Sep; 146(1):33-49. PubMed ID: 25959091
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Variable epitope library carrying heavily mutated survivin-derived CTL epitope variants as a new class of efficient vaccine immunogen tested in a mouse model of breast cancer.
    NoeDominguez-Romero A; Zamora-Alvarado R; Servín-Blanco R; Pérez-Hernández EG; Castrillon-Rivera LE; Munguia ME; Acero G; Govezensky T; Gevorkian G; Manoutcharian K
    Hum Vaccin Immunother; 2014; 10(11):3201-13. PubMed ID: 25483665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.